Galmed announces that it plans to expand its drug development activities by adding two additional programs. Galmed says it plans to release new data from in-vitro and ex-vivo studies on the new ...

In this article we will check out the progression of hedge fund sentiment towards Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) and determine whether it is a good investment right now. We at Insider Monkey ...

Galmed Pharmaceuticals Ltd. Annual cash flow by MarketWatch. View GLMD net cash flow, operating cash flow, operating expenses and cash dividends.

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile ...

GALMED PHARMACEUTICALS ($GLMD) posted quarterly earnings results on Thursday, May 22nd. The company reported earnings of -$0.62 per share, beating estimates of -$0.91 ...

Short interest in Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) decreased during the last reporting period, falling from 98.39K to 34.35K. This put 0.63% of the company's publicly available shares short.

The shares of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) are trading up 17.7% at $9.32, after B. Riley initiated coverage on the drug stock with a "buy" rating and $28 price target -- a 253% premium to ...

Investors are always looking for stocks that are poised to beat at earnings season and Galmed Pharmaceuticals Ltd. ( GLMD) may be one such company. The firm has earnings coming up pretty soon, and ...

The shares of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD)-- a company focused on treating liver diseases, including Non-Alcoholic Steatohepatitis (NASH) -- are skyrocketing today, thanks to some very ...